- Home
- QNCX vs VTGN Comparison
QNCX vs VTGN Comparison
Compare QNCX & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QNCX | VTGN |
|---|---|---|
| Founded | 2012 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.0M | 21.8M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | QNCX | VTGN |
|---|---|---|
| Price | $0.10 | $0.59 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 2 | 3 |
| Target Price | N/A | ★ $0.90 |
| AVG Volume (30 Days) | ★ 17.3M | 440.2K |
| Earning Date | 05-12-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ N/A | N/A |
| Revenue This Year | N/A | $124.49 |
| Revenue Next Year | N/A | $353.99 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.08 | $0.43 |
| 52 Week High | $4.55 | $5.14 |
Technical Indicators
Market Signals| Indicator | QNCX | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 30.57 | 45.73 |
| Support Level | $0.08 | $0.57 |
| Resistance Level | $0.98 | $0.60 |
| Average True Range (ATR) | 0.01 | 0.04 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 46.41 | 37.15 |
Price Performance
Historical ComparisonAbout QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.